Last reviewed · How we verify
NCT04386265
Compassionate Use of Hyperbaric Oxygen Therapy
trial in COVID-19 in 100 participants. Status unknown.
11 May 2022
Quick facts
| Lead sponsor | SerenaGroup, Inc. |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 15 April 2020 |
| Primary completion | 11 May 2022 |
| Estimated completion | 11 May 2022 |
| Sites | 11 locations across United States, Poland |
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
SerenaGroup, Inc. — full company profile →
Who can join
18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an observational patient registry of COVID-19 patients treated with HBOT.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The conundrum of using hyperoxia in COVID-19 treatment strategies: may intermittent therapeutic hyperoxia play a helpful role in the expression of the surface receptors ACE2 and Furin in lung tissue via triggering of HIF-1α?
Koch A, Kähler W, Klapa S, Grams B, et al · · 2020 · cited 10× · PMID 32953400 · DOI 10.1186/s40635-020-00323-1
Verify or expand the search:
- PubMed search for NCT04386265
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other SerenaGroup, Inc. trials
Trials by the same sponsor.
- NCT05198544 — Clinical Trial Evaluating a Hyaluronic Acid Matrix in the Treatment of Chronic Non-healing Diabetic Foot Ulcers (DFUs) · NA · unknown
- NCT05107050 — Comparing a Synergistic Antimicrobial Cleanser and Gel to Normal Saline and an Amorphous Gel in Reducing Bioburden and P · NA · unknown
- NCT05033470 — A Multicentre Prospective Study Evaluating an Off-loading Mattress Overlay System in Healing of Stage 3 Pressure Ulcers · NA · unknown
- NCT05076578 — A Prospective Clinical Study Evaluating the Harvesting of Micografts · NA · completed
- NCT04888624 — A Comparison Between Two Post-operative Dressings · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04386265 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by SerenaGroup, Inc.
- Last refreshed: 23 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04386265.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing